IQE puts itself in play: expanded strategic review and formal offer period
IQE has widened its strategic review to include a potential sale of the whole company and confirmed it is now in an offer period under the Takeover Code. The company has received an approach from a potential offeror, but there is no certainty an offer will be made, nor the terms if it is.
This is a Rule 2.4 announcement – an “early-stage talks” disclosure, not a firm offer under Rule 2.7. The Takeover Panel has allowed IQE not to name any potential bidder at this stage. From here, the usual disclosure rules kick in for holders above 1%, as set out in the RNS.
FY25 outlook: softer revenue and slim-to-negative EBITDA
IQE expects 2025 revenue between £90.0 million and £100.0 million. Adjusted EBITDA is guided to a range of £(5.0) million to £2.0 million. For H1 2025, the company expects at least £44.0 million of revenue and an adjusted LBITDA (loss at the EBITDA level) of £(0.4) million.
Adjusted EBITDA is earnings before interest, tax, depreciation and amortisation, adjusted for exceptional items. LBITDA simply means the adjusted EBITDA number is negative.
What is driving the weakness? Wireless and US defence timing
The update points to two clear headwinds. First, the wireless market remains soft, tied to slower mobile handset sales. Second, delays to US military and defence funding cycles are pushing orders into 2026. IQE also notes that some customers met demand from inventory built up in 2023 and 2024, which has dampened new orders in H1 2025.
In short, the order book is being squeezed from both consumer and government ends, and inventory unwind is still in the system.
Taiwan operations sale talks: potential to clean up the balance sheet
IQE is negotiating with multiple parties to sell its Taiwan operations. If completed, proceeds are expected to be used to fully repay the Group’s Revolving Credit Facility with HSBC Bank and the Convertible Loan Notes issued in March 2025, with additional cash earmarked for investment in core operations. The size of these liabilities is not disclosed in the RNS.
That is a potentially meaningful de-risking step. Deleveraging would reduce financing strain and free up management bandwidth. The flip side: execution risk on the sale, and after divestment, the group needs to ensure its remaining footprint supports growth and margins.
What the offer period means for shareholders
Being in an offer period does not mean a bid is imminent or guaranteed. It does mean the company is in formal strategic play, and there are heightened disclosure obligations for significant holders under the Takeover Code. The announcement confirms an approach has been received. There is no visibility on price, structure or timing.
Two parallel tracks are now in motion: a potential corporate sale of IQE itself, and a potential asset sale of Taiwan operations. Either could be value-shaping events, but neither is certain.
Key numbers from the RNS
| Metric | Figure |
|---|---|
| FY25 revenue guidance | £90.0m – £100.0m |
| FY25 adjusted EBITDA guidance | £(5.0)m to £2.0m |
| H1 2025 revenue (at least) | £44.0m |
| H1 2025 adjusted LBITDA | £(0.4)m |
| Interim results date | 23 September 2025 |
| Status under Takeover Code | Offer period (Rule 2.4 announcement) |
| Potential offeror | Approach received; identity not disclosed |
| Taiwan operations | Negotiations for sale ongoing |
| Use of Taiwan sale proceeds | Repay HSBC RCF and March 2025 CLNs; invest in core |
| RCF and CLN amounts | Not disclosed |
Quick primer: what IQE actually does
IQE supplies compound semiconductor wafers, made using epitaxy – a process that grows ultra-thin crystalline layers to create high-performance chips. These materials enable applications across smart devices, communications infrastructure, automotive and industrial, and aerospace and security. The market has high barriers to entry and quality, yield and cost per unit matter a lot.
My take: balanced but with clear execution hurdles
On the positive side, management is taking active steps to unlock value: widening the strategic review, entertaining a company sale, and seeking to sell a non-core operation to reduce debt and reinvest in the core. The guidance implies the business can stay within touching distance of EBITDA breakeven even in a tough year, which should limit cash burn if delivered.
On the negative side, end-market timing is not in IQE’s control. Wireless remains weak and defence orders are delayed to 2026, which could keep utilisation and margins under pressure. The Taiwan sale and any potential offer are not done deals, and valuation outcomes are unknown.
Net-net, this is a classic “optionality” setup: tough trading now, but with multiple corporate actions that could reshape the equity story. The immediate share reaction will likely track perceived deal probability and the tone of the interim results later this month.
What to watch next
- 23 September 2025 – interim results: more detail on H1 trading, cash, and outlook for H2.
- Taiwan operations sale: price, buyer, and timing. Proceeds versus debt to be repaid are key.
- Any move from potential offerors: a Rule 2.7 firm offer, or an end to talks.
- Wireless demand and inventory unwinding: signs of normalisation in handset supply chains.
- US defence funding cadence: whether deferred orders convert into 2026 visibility.
Jargon buster
- Offer period: a formal period under the Takeover Code when a company is subject to potential offer activity and additional disclosure rules.
- Rule 2.4 vs Rule 2.7: Rule 2.4 is an early-stage talks notification; Rule 2.7 is a firm intention to make an offer.
- Adjusted EBITDA/LBITDA: profit (or loss) measure before interest, tax, depreciation and amortisation, adjusted for specific items.
- RCF: Revolving Credit Facility – a flexible bank lending line.
- Convertible Loan Notes (CLNs): debt that can convert into equity on set terms.
Bottom line
IQE is navigating a tough demand backdrop while opening the door to strategic change, including a potential sale of the company. Guidance points to a challenging 2025, but management is targeting balance sheet repair through an asset sale and keeping optionality alive with the wider review. There is no certainty of a bid or a Taiwan deal; near-term catalysts will be crucial in setting expectations for 2026.
